Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 1
2020 1
2021 4
2022 6
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
A Case of Adult-onset Still's Disease (AOSD) with Gastrointestinal Lesions.
Harada T, Hirata Y, Kawamura H, Yamamoto Y, Kobayashi Y, Kumai D, Adachi A, Nagura Y, Ikeuchi H, Hayashi N, Takada H, Sobue S, Yoshida M. Harada T, et al. Among authors: nagura y. Intern Med. 2024 Apr 16. doi: 10.2169/internalmedicine.3412-23. Online ahead of print. Intern Med. 2024. PMID: 38631856 Free article.
Prognostic nutritional index after introduction of atezolizumab with bevacizumab predicts prognosis in advanced hepatocellular carcinoma: A multicenter study.
Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Kato D, Kusakabe A, Koguchi H, Hasegawa I, Matoya S, Miyaki T, Kimura Y, Tanaka Y, Kondo H, Ozasa A, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H; Sakurayama Liver Study Group. Suzuki T, et al. Among authors: nagura y. Oncology. 2024 Jan 18. doi: 10.1159/000536367. Online ahead of print. Oncology. 2024. PMID: 38237558
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Matoya S, Miyaki T, Kimura Y, Kusakabe A, Narahara S, Tokunaga T, Nagaoka K, Kuroyanagi K, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Suzuki T, et al. Among authors: nagura y. Cancer Med. 2023 Dec 22;13(1):e6876. doi: 10.1002/cam4.6876. Online ahead of print. Cancer Med. 2023. PMID: 38133557 Free PMC article.
The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
Matoya S, Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, Kuroyanagi K, Kusakabe A, Koguchi H, Hasegawa I, Miyaki T, Tanaka Y, Kondo H, Kimura Y, Ozasa A, Kawamura H, Kuno K, Fujiwara K, Nojiri S, Kataoka H; Sakurayama Liver Study Group (SLSG). Matoya S, et al. Among authors: nagura y. Hepatol Res. 2023 Jun;53(6):511-521. doi: 10.1111/hepr.13886. Epub 2023 Feb 18. Hepatol Res. 2023. PMID: 36723964
Efficacy of minocycline hydrochloride aspiration sclerotherapy with additional monoethanolamine oleate aspiration sclerotherapy for symptomatic hepatic cysts.
Kimura Y, Fujiwara K, Matsuura K, Suzuki T, Senoo K, Tsuchida K, Mori Y, Hirano A, Nomura S, Kitagawa M, Tomita Y, Kanaiwa H, Imazu M, Nagura Y, Nojiri S, Kataoka H. Kimura Y, et al. Among authors: nagura y. Hepatol Res. 2023 Mar;53(3):267-275. doi: 10.1111/hepr.13865. Epub 2022 Dec 15. Hepatol Res. 2023. PMID: 36479738
Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation.
Suzuki T, Matsuura K, Urakabe K, Okumura F, Kawamura H, Sobue S, Matoya S, Miyaki T, Kimura Y, Kato D, Kusakabe A, Tanaka Y, Ozasa A, Nagura Y, Fujiwara K, Nojiri S, Hagiwara S, Kusumoto S, Inoue T, Tanaka Y, Kataoka H. Suzuki T, et al. Among authors: nagura y. Hepatol Res. 2023 Apr;53(4):289-300. doi: 10.1111/hepr.13864. Epub 2022 Dec 16. Hepatol Res. 2023. PMID: 36461885
Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.
Nagura Y, Matsuura K, Iio E, Fujita K, Inoue T, Matsumoto A, Tanaka E, Nishiguchi S, Kang JH, Matsui T, Enomoto M, Ikeda H, Watanabe T, Okuse C, Tsuge M, Atsukawa M, Tateyama M, Kataoka H, Tanaka Y. Nagura Y, et al. PLoS One. 2022 Feb 14;17(2):e0263844. doi: 10.1371/journal.pone.0263844. eCollection 2022. PLoS One. 2022. PMID: 35157730 Free PMC article.
18 results